Bernard J. Zovighian, CEO and Director of Edwards Lifesciences Corp, filed a Form 4 on November 9, 2026, disclosing the exercise of employee stock options and the subsequent sale of common stock under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Zovighian exercised 23,100 employee stock options at an exercise price of $72.68 per share on November 9, 2026.
  • First sale: 9,184 shares were disposed of at a weighted average price of $103.3851, with individual trades ranging from $103.18 to $103.66.
  • Second sale: 13,916 shares were disposed of at a weighted average price of $102.7803, with individual trades ranging from $102.17 to $103.16.
  • Remaining direct ownership: Following the transactions, Zovighian directly owned 98,845 shares of common stock.
  • Indirect holdings: The filing also reports 3,733.5603 shares held indirectly via a 401(k) and 8,915.6499 shares held indirectly by trust.
  • 10b5-1 plan: All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Zovighian on July 28, 2026.

Zovighian's Option Exercise and Share Sales at Edwards Lifesciences

According to the filing, Bernard J. Zovighian, who serves as both CEO and Director of Edwards Lifesciences Corp (NYSE:EW), reported a series of transactions in the company's common stock on November 9, 2026. The activity began with the exercise of 23,100 employee stock options at a conversion price of $72.68 per share. These options were originally granted on May 7, 2020, under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program, and were scheduled to vest in four equal annual installments commencing one year after the grant date, according to the filing.

Following the exercise, the filing discloses two separate sales of common stock on the same date. The first sale covered 9,184 shares at a weighted average price of $103.3851, executed across multiple trades priced between $103.18 and $103.66. The second sale involved 13,916 shares at a weighted average price of $102.7803, with individual trade prices ranging from $102.17 to $103.16. The filing notes that full detail on the number of shares and prices at which each transaction was effected is available upon request to the SEC staff, the issuer, or a security holder.

All three transactions - the option exercise coded "M" and the two sales coded "S" - were carried out under a Rule 10b5-1 trading plan that Zovighian adopted on July 28, 2026, the filing states. After the reported transactions, Zovighian's direct beneficial ownership stood at 98,845 shares. The remaining employee stock options reported in Table II total 23,100 shares directly held, with an expiration date of May 6, 2027. The filing carries a note that it "reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person."

What Was Disclosed

Edwards Lifesciences CEO Bernard J. Zovighian reported the exercise of 23,100 stock options and the sale of a combined 23,100 shares of common stock on November 9, 2026, all executed under a pre-adopted Rule 10b5-1 plan, leaving him with 98,845 directly owned shares.